In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...

One of biggest stories or developments in acute myeloid leukemia or AML is the wider adoption and use of the regimen of ...

Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...

Scientists have uncovered how leukemia cells manage to escape one of the most commonly used treatments. Over time, these cancer cells subtly change the shape of their mitochondria to avoid dying when ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...

East Neck Nursing & Rehab will host a holiday fundraiser to support the Berry family as their 17-month-old son undergoes ...